<DOC>
	<DOCNO>NCT02173158</DOCNO>
	<brief_summary>Study Evaluate Efficacy Safety Lomitapide Japanese Patients Homozygous Familial Hypercholesterolemia ( HoFH ) Concurrent Lipid-Lowering Therapy .</brief_summary>
	<brief_title>Efficacy Safety Lomitapide Japanese Patients With HoFH Concurrent Lipid-Lowering Therapy</brief_title>
	<detailed_description>This Phase 3 , single-arm , open-label , multicenter clinical trial evaluate efficacy long-term safety lomitapide Japanese patient HoFH receive maximally-tolerated , stable lipid-lowering therapy . This study comprise two phase : primary 26-week Efficacy Phase follow 30-week Safety Phase .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>1 . Japanese male female HoFH patient age ≥ 18 year age 2 . Diagnosis functional HoFH 3 . Body weight ≥ 40 kg &lt; 136 kg 4 . Negative pregnancy test screen 1 . Uncontrolled hypertension 2 . History chronic renal insufficiency 3 . History biopsy proven cirrhosis abnormal liver function test ( LFTs ) screen 4 . Any major surgical procedure occur &lt; 3 month prior screen visit 5 . Cardiac insufficiency 6 . Previous organ transplantation 7 . History nonskin malignancy within previous 3 year 8 . Patients able limit alcohol intake 9 . Participation investigational drug study within 6 week prior screen visit 10 . Known significant gastrointestinal bowel disease 11 . Nursing mother 12 . Serious unstable medical psychological condition 13 . Requirement certain prohibited medication know potentially hepatotoxic 14 . Use strong moderate inhibitor CYP3A4 15 . Use simvastatin dos &gt; 10 mg per day 16 . Documented diagnosis liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>